FDA Cancels Panel Meeting on Merck Surgery Drug

March 13, 2015 9:23 PM

4 0

The U.S. Food and Drug Administration has canceled an advisory committee's meeting to review Merck & Co.'s sugammadex, further delaying the surgery drug.

Merck said the agency intends to conduct more inspections of sites involved in a study of patient hypersensitivity to the drug. Merck said it expects to receive a letter from the FDA by April 22, the targeted action date, saying the application is not yet ready for approval. Merck said it would cont...

Read more

To category page

Loading...